The cost of finding gaps late
Why a gap analysis before submission is cheaper than the deficiency letter after it.
Newsletter · written by Maik Endler
Maik writes about real cases where a regulatory decision moved the whole company: launch dates, cash, suppliers, the team. A management view of regulation, told as a conversation, not a list of new rules.
No fixed schedule: Maik writes when there is a case worth telling.
No spam. Unsubscribe with one click.
What each letter brings
Written as a conversation, not a bulletin. The regulatory team gets the precision. The owner, the CEO and the operations lead get what is at stake.
A client story or a day-to-day situation: a deficiency letter with 30 days to answer, a supplier change, an audit next month.
Launch dates, revenue on hold, stock waiting at the border, work paid for twice, a distributor asking for answers.
What he would decide first, who needs to be involved and where the regulatory point really changes the plan.
Recent letters
A short summary of each letter. The full text goes to subscribers only.
Why a gap analysis before submission is cheaper than the deficiency letter after it.
When published literature and existing data can carry part of the biological evaluation.
What to do when your team is at capacity and a deadline is not moving.
There is no fixed schedule. Maik writes when there is a real case worth telling, so every letter has something to say.
No. Rule changes appear when they matter, but the focus is how regulatory decisions affect the business: time to market, cost, supply chain and the team.
It is a conversation about real cases. When it fits the situation, Maik mentions how Sobel can help. If you want to talk about your own case, just reply.
English and Portuguese. You choose when you subscribe, and replies go to Maik.
Every email has a one-click unsubscribe link at the bottom.
Subscribe to our newsletter to receive the latest updates and insights.
You may unsubscribe at any time using the link in our newsletter.